Atossa Therapeutics authorizes $10M stock repurchase program through Dec 31, 2023

ATOSSA THERAPEUTICS, INC.

Board approved repurchase of up to $10M of common stock through December 31, 2023.
Program is less than 10% of total cash as of March 31, 2023; cash runway exceeds three years.
Repurchases may occur in open market or private transactions; no obligation to buy any shares.
CEO states confidence in strategic priorities; CFO cites attractive valuation opportunity.
Program may be suspended, modified, or terminated at any time without prior notice.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.